Brian C. Deschuytner

Chief Operating Officer & Chief Financial Officer at Mersana Therapeutics

Brian joined Mersana in 2019, bringing significant biopharmaceutical business strategy, operational, finance, product development, and commercialization experience from leading oncology companies. Prior to Mersana, he served as Vice President at TESARO, where he was responsible for the commercialization of ZEJULA® (niraparib), a PARP inhibitor developed to treat ovarian cancer. From 2009 to 2017 Brian held several positions of increasing responsibility at Takeda Oncology (previously known as Millennium Pharmaceuticals), where he served as Vice President, responsible for the global launch of NINLARO® (ixazomib), a drug developed to treat multiple myeloma. At Takeda Oncology and earlier in his career at Novartis, Brian held corporate development and strategy roles, and was a leader in the life sciences practice of L.E.K. Consulting.

Brian holds an M.B.A from the Wharton School of the University of Pennsylvania and a B.A. in Biophysical Chemistry from Dartmouth College.

In his free time, Brian enjoys hiking, rock climbing, and Star Wars. Many people even say that Brian reminds them of Han Solo.

Links

Previous companies

Novartis logo
TESARO logo